J&J to Acquire Abiomed for US$16.6 B

By Ayush Saxena

Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)

Published: 11 Nov-2022

DOI: 10.3833/pdr.v2022.i11.2747     ISSN: 1756-7874

Section: Mergers & Acquisitions



In an attempt to strengthen its medical device division, Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Abiomed for an upfront payment of US$380 per share, representing a total deal value of US$16...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details